{
  "trial_id": "NCT02247440",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Evidence of chronic HCV infection for at least 6 months before study entry (at least one detectable HCV viral load, i.e. \u226517 IU/mL, with an antibody test positive at least 6 months before the HCV RNA load result)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Fibrosis Stage F2-3-4 determined by transient elastography (Fibroscan or other similar equipment). During the first part of the study, priority will be given to patients with Fibrosis Stage F2-3.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Anemia and thrombocytopenia",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any conditions that, in the investigator's judgment, may compromise the follow up.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Contra-indication to study treatment (including pregnancy or lack of effective contraception in the participant or female partner)",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has chronic HCV infection for at least 6 months and fibrosis stage F2-3. However, there is no clear indication of severe liver damage, advanced stage cirrhosis or cancer.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT02247440",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}